EHA 2022 | Current and emerging therapeutic strategies in beta-thalassemia
Ali Taher, MD, PhD, American University of Beirut Medical Center, Beirut, Lebanon, discusses the current standard of care (SOC) in beta-thalassemia, highlighting novel therapeutic strategies for this disease. Prof. Taher explains that whilst curative strategies such as bone marrow transplantation (BMT), and emerging strategies targeting erythropoiesis and the alpha:beta imbalance observed in beta-thalassemia, are being developed, transfusion and iron chelation therapy will remain the SOC in third-world countries. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Novartis Pharmaceuticals: Consultancy, Research funding; Bristol-Myers Squibb (Celgene): Consultancy, Research funding; Ionis Pharmaceuticals: Consultancy, Research Funding; Vifor: Consultancy, Research Funding; Imara: Consultancy, Research Funding; Agios: Consultancy
